Leerink Swann Raises Price Target on Regeneron (REGN) to $182
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/25/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Outlook Therapeutics (OTLK) halted, news pending
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
Regeneron (REGN) Says EYLEA Clinically Equivalent to Lucentis Following VIEW 1, 2 Phase 3s
October 18, 2012 4:25 PM EDTRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that detailed one-year results from the VIEW 1 and VIEW 2 Phase 3 studies of EYLEA (aflibercept) Injection were published online in the journal Ophthalmology ahead of a future print publication. The publication can be accessed at http://digitalreprints.elsevier.com/t/28599.
"The article published today provides additional details about the VIEW 1 and VIEW 2 studies that demonstrated that EYLEA offered similar improvements in visual acuity to monthly ranibizumab, but with less... More
